{"id":"W1814864706","doi":"10.1517/13543784.2011.562190","title":"Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Rivaroxaban; Apixaban; Medicine; Edoxaban; Dosing; Clinical trial; Intensive care medicine; Anticoagulant; Fondaparinux; Dabigatran; Pharmacodynamics; Atrial fibrillation; Discovery and development of direct thrombin inhibitors; Thrombosis; Pharmacokinetics; Pharmacology; Warfarin; Internal medicine; Venous thromboembolism; Thrombin","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006805926,0.0008203659,0.001252209,0.002233882,0.0001820252,0.0006615575,0.0006283752,0.001033497,0.009214483],"category_scores_gemma":[0.000891596,0.0001924366,0.0006151801,0.00278773,0.0003523781,0.001016951,0.000448846,0.001203711,0.005768109],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004090049,"about_ca_system_score_gemma":0.001171344,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007994808,"about_ca_topic_score_gemma":0.001417966,"domain_scores_codex":[0.9996452,0.00006921196,0.00004636211,0.00004352133,0.0001677382,0.00002791577],"domain_scores_gemma":[0.9994859,0.0001724698,0.0001541598,0.00001297809,0.0001457821,0.00002860332],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008550377,0.00005252093,0.0001519194,0.02168594,0.0001039349,0.0002296829,0.00004695275,0.0001285452,0.0008174336,0.002088586,0.07170974,0.9028993],"study_design_scores_gemma":[0.0000523272,0.0000705827,0.001033111,0.007275233,0.0001373106,0.001680792,0.00002960152,0.00004684487,0.0002528536,0.0009781776,0.9884316,0.00001167744],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007980466,0.9960023,0.0001204914,0.0005825452,0.0004773288,0.00001311221,0.00003286829,0.000007654137,0.002683969],"genre_scores_gemma":[0.0007407129,0.9962276,0.0002196564,0.0005169277,0.0005518167,0.00001535992,0.0000617962,0.000001819976,0.001664372],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009214483,"threshold_uncertainty_score":0.03082556,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2905933212457546,"score_gpt":0.4304623271137995,"score_spread":0.1398690058680449,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}